Monica Ganzinelli

Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial

Marina Chiara Garassino, Olga Martelli, Massimo Broggini et al. · The Lancet Oncology · 2013 · 476 citations

Second-line Treatment, Oncology, Wild-type Egfr Tumours +9

Antibody–Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non–small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade

Giuseppe Lo Russo, Massimo Moro, Michele Sommariva et al. · Clinical Cancer Research · 2018 · 400 citations · Full text

Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors

Giovanni Fucà, Giulia Galli, M. Poggi et al. · ESMO Open · 2019 · 203 citations · Full text

Patient-Derived Ovarian Tumor Xenografts Recapitulate Human Clinicopathology and Genetic Alterations

Francesca Ricci, Francesca Bizzaro, Marta Cesca et al. · Cancer Research · 2014 · 127 citations

Tumoral Pathology, Xenotransplantation, Malignant Disease +13

Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC

Massimo Moro, Elisa Caiola, Monica Ganzinelli et al. · Journal of Thoracic Oncology · 2018 · 103 citations · Full text

Prevents Resistance, Cell Regulation, Medicine +10